96969-83-4

Human sirtuin 2 (SIRT2) is a NAD⁺-dependent protein deacetylase with diverse targets, including α-tubulin, phosphoenolpyruvate carboxykinase, and forkhead box protein O1. JFD00244 is an inhibitor of SIRT2 (IC₅₀= 56.7 μM). At 5 μM, JFD00244 induces granulocytic differentiation in the acute promyelocytic leukemia cell line NB4.

BML-266 is an inhibitor of SIRT2.

ChEBI: 1,4-bis[2-(4-hydroxyphenyl)ethylamino]anthracene-9,10-dione is an anthraquinone.

in a previou study, the molecular modeling and virtual screening were utilized to identify potential compounds, which were then subjected to experimental tests for their sirt2 inhibitory activity. five of the 15 tested compounds including jfd00244 displayed inhibitory activity toward sirt2, resulting in a hit ratio of 33% in a micromolar level. jfd00244 and another analog of the five compounds yielded in vitro ic(50) values of 56.7 and 74.3 microm, respectively. on the basis of these results, a phenol moiety on the active compounds including jfd00244 was suggested to be critical for sirt2 inhibitory activity. this phenol group, together with a hydrophobic moiety and hydrogen-bonding features, was thus recommended to form an active sirt2 pharmacophore [1].

56.7 μm

[1] tervo aj, kyrylenko s, niskanen p, salminen a, leppnen j, nyrnen th, jrvinen t, poso a. an in silico approach to discovering novel inhibitors of human sirtuin type 2. j med chem. 2004 dec 2;47(25):6292-8.